Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
Phio Pharmaceuticals Corp. (PHIO), a Delaware corporation listed on The Nasdaq Capital Market, filed this Current Report on Form 8-K on May 7, 2026. The filing announces the reporting of financial results for the quarterly period ended March 31, 2026.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. The document serves as a notification that results have been reported, with details available in the attached press release.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. The report explicitly states that the information in Item 2.02 and Exhibit 99.1 is not treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference unless expressly stated in another filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 financial figures including revenue, net loss, and cash position.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the company provided updated full-year 2026 guidance in the press release.